SOUTH SAN FRANCISCO, Calif.,
Oct. 2, 2018 /PRNewswire/ -- Titan
Pharmaceuticals, Inc. (NASDAQ: TTNP), a commercial stage company
developing proprietary therapeutics for the treatment of select
chronic diseases utilizing its ProNeura™ long-term, continuous drug
delivery technology, today announced the appointment of
Dane D. Hallberg to the newly
created position of Executive Vice President and Chief Commercial
Officer, effective immediately. Mr. Hallberg will be responsible
for leading all of the company's commercial activities.
"Dane brings to Titan important experience and depth of
knowledge in sales and marketing, product launch and market access
as we relaunch Probuphine and work to maximize this commercial
opportunity," said Titan's President and CEO, Sunil Bhonsle. "He was a key member of the team
responsible for launching Merck's Implanon subdermal implant
contraceptive, and we are thrilled to have an executive of his
caliber join our team in this important new position."
Mr. Hallberg has a strong track record of success in the global
pharmaceutical and biotech industries, building out commercial
capabilities, leading marketing and sales teams, and cultivating
strong thought leader relationships across multiple specialties.
His 22 years of healthcare experience includes commercial
leadership roles with Able Star, LLC, Sunovion Pharmaceuticals
Inc., Merck, Global Healthcare Japan (acquired by Aetna), Dendrite
Japan K.K. (IQVIA) and Tierra Incorporated. Most recently, he was
retained by Bristol-Myers Squibb as a consultant to provide
strategic guidance and project management for its global research
and development, business intelligence and analytics, and health
economics and outcomes research programs. Mr. Hallberg received a
B.S. and M.A. from Western Illinois
University, and completed the Executive Leadership Program
at Cornell University.
"I have been consulting with Titan to help evaluate the market
for opioid use disorder and start laying the necessary groundwork
and strategies to position Probuphine for success," said Mr.
Hallberg. "Based on that early work, I am confident there is a
significant and growing market for Probuphine, which has the
potential to address important unmet needs in this global epidemic.
I am excited to take on this new role with the company."
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a commercial stage
company developing proprietary therapeutics with its ProNeura™
long-term, continuous drug delivery technology. The company's lead
product is Probuphine® (buprenorphine) implant, a novel
and long-acting formulation of buprenorphine for the long-term
maintenance treatment of opioid dependence. Approved by the FDA in
May 2016, Probuphine is the first and
only commercialized treatment of opioid dependence to provide
continuous, around-the-clock blood levels of buprenorphine for six
months following a single procedure. The ProNeura technology also
has the potential to be used in developing products for treating
other chronic conditions such as Parkinson's disease and
hypothyroidism, where maintaining consistent, around-the-clock
blood levels of medication may benefit the patient and improve
medical outcomes. For more information about Titan, please visit
www.titanpharm.com.
Forward-Looking Statements
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our
product development programs and any other statements that are not
historical facts. Such statements involve risks and uncertainties
that could negatively affect our business, operating results,
financial condition and stock price. Factors that could cause
actual results to differ materially from management's current
expectations include those risks and uncertainties relating to the
commercialization of Probuphine, the regulatory approval process,
the development, testing, production and marketing of our drug
candidates, patent and intellectual property matters and strategic
agreements and relationships. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as
required by law.
CONTACTS:
Sunil Bhonsle,
President & CEO
(650) 244-4990
Stephen Kilmer
Investor Relations
(650) 989-2215
skilmer@titanpharm.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/titan-strengthens-executive-leadership-team-with-appointment-of-chief-commercial-officer-300722477.html
SOURCE Titan Pharmaceuticals, Inc.